Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 4Neoplasms 2Leukemia 2Recurrence 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Glioma 1Chondrosarcoma 1Cholangiocarcinoma 1

Interventions

Cytarabine 7Idarubicin 3Etoposide 3Daunorubicin 3Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Cyclophosphamide 2Clofarabine 2valspodar 1tipifarnib 1pegylated granulocyte colony-stimulating factor 1fludarabine phosphate 1enasidenib 1aldesleukin 1Whole-Body Irradiation 1Vorinostat 1Topotecan 1Pravastatin 1Mycophenolic Acid 1Mitoxantrone 1Lenalidomide 1Gemtuzumab 1Cyclosporine 1Calicheamicins 1Busulfan 1Bortezomib 1Bone Marrow Transplantation 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Monocytic, Acute × enasidenib × Clear all
NCT05282459 2026-04-17

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Stanford University

Phase 1/2 Completed
17 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Leukemia, Monocytic, Acute, Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡